Moderna (MRNA) stock contnues to tumble as J.P. Morgan and Jefferies downgrade the biotech following updates at the company's ...

Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

By investing heavily on EV R&D, India can further localise production to create more jobs, tap export markets to gain global ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna will slash five clinical programmes but says it remains on track for ten product approvals in the next three years.

Moderna MRNA announced a strategic overhaul and new financial guidance at its R&D day on Sept. 12, and we’ve lowered our fair value estimate to $141 per share from $227. We’ve repeatedly ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

today announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline at its annual R&D Day event. The updates include data readouts in the Company ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna Inc.’s shares (NASDAQ:MRNA) sank 19% to a $64.11 low in early trading Sept. 12 as investors learned during the annual ...

Even if you aren’t a slave to a fitness tracker, the concept of walking 10,000 steps a day is ingrained as a general health ...